Upregulated expression of LILRA6 has been observed in patients with Multiple Sclerosis [47], severe aplastic anemia [48], rheumatoid arthritis [49], and non-small cell lung cancer following neoadjuvant chemo-immunotherapy [50]. Here, LILRA6 is linked to multiple sclerosis.